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Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239 S209hemorrhagic myocarditis. We present 2 cases of successful
engraftment after emergent substitution of ﬂudarabine (FLU)
for CY due to acute cardiac toxicity. Case 1 is a 6-mo-old
female with 11q23+ AML who underwent MRD BMT in CR1
with a planned preparative regimen of BU/CY. BU adminis-
trationwas completedwith targeted PKs; however, screening
creatine kinaseprior to scheduledCYadministrationonday-5
showed a markedly elevated level of 301 IU/dl with a normal
EKG. Troponin1 level was also very elevated at 0.49 ng/ml.
Fludarabine (FLU) was substituted for CY at 1.3mg/kg/dose
from day -5 through day -2. Neutrophil and platelet engraft-
ment occurred on day +11 and she remains 99% donor 3 yrs
post-BMT. Case 2 is a 3-yr-old female with primary myeloﬁ-
brosis who underwent a 10/10 MUD HSCT with a planned
preparatory regimen of CY/TBI. She received one dose of CYat
60 mg/kg but developed low voltage on her screening EKG
prior to the second dose. CKwas normal. FLUwas substituted
for the remaining dose of CY at 30 mg/m2/dose and she
received the planned 1200 cGy TBI. She had neutrophil
engraftment on day +32 and platelet engraftment on day +96.
She remained 100% donor but unfortunately died 10 months
post-BMT due to GVHD. Both patients had no further cardio-
vascular toxicity other than hypertension. CY induced hem-
orrhagic myocarditis is invariably fatal. Screening tests with
serum CK and EKG may be used to predict early signs of car-
diac toxicity. In the acute setting of cardiac toxicity, FLU offers
an appropriate therapeutic substitution to avoid further car-
diac toxicity and allow successful engraftment.275
Preemptive Immunotherapy Based on Post-Transplant
Chimerism and MRD Monitoring Is an Effective Strategy
to Prevent Relapse after Allogeneic Stem Cell
Transplantation in Children with ALL: A Single Center
Experience
Peter Bader 1, Eva Rettinger 1, Michael Merker 1,
Hermann Kreyenberg 1, Thomas Krenn 2, Matthias Dürken 3,
Jörg Faber 4, Sabine Huenecke 1, Claudia Brehm1,
Melanie Bremm1, Andre Willasch 1,
Emilia Salzmann-Manrique 1, Andrea Jarisch 1, Jan Soerensen 1,
Evelyn Ullrich 1, Thomas E. Klingebiel 1. 1 Stem Cell
Transplantation and Immunology, Klinik für Kinder und
Jugendmedizin, Frankfurt, Germany; 2 University Children’s
Hospital, Homburg Saar, Germany; 3 University Children’s
Hospital, Mannheim, Germany; 4 University Children’s Hospital,
Mainz, Germany
Introduction: Mixed chimerism (MC) and MRD strongly
predict relapse in children with ALL after allo-SCT. Pre-
emptive immunotherapy (IT), e.g. withdrawal of immuno-
suppression (WD-IS) or DLI can prevent impending relapse.
In this study we retrospectively analyzed chimerism and
MRD monitoring and the effect of pre-emptive IT.
Patients: Between January 2005 and July 2014, a total of 89
pts with ALL (pB-ALL, n¼63; T-ALL, n¼20; biphen. ALL, n¼6)
received allo-SCT in our institution. 47 pts were in CR1, 26 pts
in CR2, 15 pts were CR3 and 1 pt CR4 at time of transplant.
Donors were MSD (n¼18), MUD (n¼61) and haploidentical
(n¼10). Conditioning consisted of TBI (12 Gy) and ETO in pts
with a matched donor and FLU, THIO, MEL in haplo pts.
Methods: Chimerism was assessed weekly in peripheral
blood until day 200 and monthly thereafter. Bone marrow
analyses were done at days +30, +60, +90, +180 and +365
post-transplant. Thereby, MRD was assessed in 56 pts,
whereas no diagnostic material was available in 33 pts.
Results: 64/89 pts (72%) showed complete chimerism (CC) in
all follow-up analyses, and 25/89 pts (28%) developed MC.From 56 pts in whom MRD could be assessed, 40 pts
remained MRD negative and 16 developed MRD positivity
after transplantation. IT (WD-IS, n¼12; DLI, n¼14) was
initiated based on chimerism analysis in 22/25 pts with MC,
and was guided by MRD detection in 4 pts. For the total
cohort of pts, pEFS and pOS were 0.67 and 0.77, respectively.
Cumulative incidence (CI) of TRM and relapse (CI-R) were
0.11 and 0.24 for all pts.
Chimerism: pEFS was 0.74 in CC-pts and 0.51 in MC-pts
(p<0.032). 22/25MC-pts received pre-emptive IT resulting in
a pEFS of 0.58. Due to rapid progression IT was not initiated
in 3/25 MC pts. All MC pts without IT relapsed. While CI-TRM
remained low (0.10 for CC resp. 0.12 for MC, p>0.68) in both
groups, CI-R was 0.17 in CC- and 0.41 in MC-pts (p<0.021).
MRD: Pts were grouped according to their highest MRD
value post-transplant in MRD negative, low positive (<10E-
4), and high positive (>10E-4) pts. pEFS and pOS were 0.82
and 0.95 in MRD negative (n¼40), 0.56 and 0.88 in low level
MRD (n¼8), and 0.25 and 0.25 in high level MRD (n¼8)
positive pts (p<0.001). CI-Rwas 0.14 inMRD negative, 0.36 in
MRD low, and 0.75 inMRD high positive pts (p<0.001), while
CI-TRM between these groups remained low (0.05 for MRD
negative, 0.13 for MRD low and 0.00 for MRD high, p>0.55).
Multivariate analysis: Multivariate analysis for pEFS also
indicated that MC and high level MRD were independent
poor prognostic factors (MC, p<0.049, RR 3.16 and high level
MRD, p<0.022, RR 3.99), while remission status before
transplantation, ALL lineage, donor type, graft source, T cell
depletion or sex showed no signiﬁcant inﬂuence.
Conclusion: Our results show that analysis of chimerism and
MRD allow the prediction of impending relapse in virtually
all pts with ALL and that pre-emptive IT can improve
outcome in these pts.276
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Introduction: The optimal timing of Alemtuzumab admin-
istration during RTC regimen is not well studied. Proximal
administration may lead to more in vivo T cell depletion,
decreasing GVHD but potentially increasing graft failure (GF)
and delaying immune reconstitution. Intermediate admin-
istration may improve engraftment but could lead to higher
rates of GVHD. We compared two centers’ experiences
studying the schedule of Alemtuzumab within Busulfan/
Fludarabine RTC regimen.
Methods: Pts21 years old undergoing alloHCT formalignant
and non-malignant conditions using a Busulfan-12.8-16mg/kg
Table 1
Day Whole Blood Chimerism CD4(cells/uL) CD8(cells/uL) CD56(cells/uL)
PG IG p PG IG p PG IG p PG IG p
30 91.821.8 93.419.8 0.765 25.848.3 76.2592.97 0.198 6.410.4 105.099.5 0.142 146.7104.1 66.877.8 0.189
100 94.27.8 95.84.6 0.399 51.038.1 113.084.1 0.001 77.2116.5 203.5258.1 0.020 256.8138.4 217.1125.1 0.270
180 93.06.2 92.712.1 0.911 148.8134.3 283.6163.6 0.003 156.0146.3 399.8358.9 0.004 252.9148.7 260.2132.5 0.857
365 89.910.0 91.915.7 0.574 583.7346.8 784.1589.1 0.280 593.9564.9 599.6367.4 0.974 350.8377.0 285.0204.5 0.508
In the UCB sub-analysis of PG pts (n¼12), compared to remaining donor sources (n¼25), a higher incidence of viral disease (33% vs. 16%, p¼0.4), viral reactivation
(58% vs. 32%, p¼0.1), and GF (p¼0.0001) and TRM (p¼0.008) was noted, respectively. The 1 yr OS in the UCB cohort was 67%, p¼0.03.
Table 1
Relapsed (n¼22) Non-relapse
(n¼41)
Patient Characteristics
Median Age at Transplant (yrs) 10 7.2
Gender
M 12 29
F 10 12
Ethnicity
Caucasian 9 19
Hispanic 10 12
Others 3 10
De novo AML 15 34
Secondary AML/MDS 7 7
Risk Stratiﬁcation
High Risk 13 27
Intermediate Risk 9 12
Unknown 0 2
Remission Pre HCT
CR1 14 17
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zumab (45-54mg/m2) regimen were included. Pts received
Alemtuzumab either Days -6 to -2 (proximal group [PG]) or
from Days -12 to -9 (intermediate group [IG]).
Results: 37 pts were included in PG and 39 in IG. Donor
Sources in PGwere related¼20 (54%) and unrelated¼17 (46%)
vs. 14 (36%) and 25 (64%) in IG, respectively (p<0.001). Five
pts (14%) in PG had an underlying malignancy vs 2 pts (5.1%)
in IG. Stem Cell Sources in PG were: BM¼18 (49%), PBSC¼4
(11%), related CB¼3 (8%), unrelated CB (UCB)¼12(32%); in IG,
BM¼27 (69%), PBSC¼12 (31%). Tomaximize the homogeneity,
the UCB in the PG group were analyzed separately. Kinetics of
immune reconstitution are in Table 1 (excludes UCB). The
incidence of viremia in PG vs. IG was comparable, p¼0.3.
Signiﬁcantly higher CMV disease was seen in PG vs. IG
(16.7% vs. 2.6%, p¼0.03), respectively. Higher TRM was seen
in IG vs. PG: 12.8% vs. 0%(p¼0.06), respectively. Rates of GF
were comparable (p¼1), while PG had a higher incidence of
grade II-IV acute GVHD (32% vs. 12.8%, p¼0.1). The OS at 1
year in PG was 96% vs. 79.5%(p¼0.07) in IG.
Discussion: Pts receiving PG had delayed immune recon-
stitution which did not impact OS. Chimerism was compa-
rable between the two groups. The optimal timing of
Alemtuzumab administration remains unclear; however,
UCB is associated with inferior outcomes. Larger studies
evaluating outcomes and health care utilization/cost are
needed.MDS 3 9
CR2 5 13
Unknown 0 2
Transplant Characteristics
Median Time to Transplant
(days)
108 (55-492) 139 (16-1349)
Donor
Matched Related Donor 11 12
Alternative Donor 11 29
Stem Cell Source
PBSC 16 24
BM 5 6
Cord 1 11
Conditioning
MAC 13 32
RIC 9 9
GVHD Prophylaxis
Cyclosporine based 21 40
Tacrolimus based 1 1
Median Cell Doses
TNC dose (x108/kg) 7.3 (0.95-12.6) 5.7 (0.34-30.7)
CD34+ dose (x106/kg) 6.0 (2.45-13.0) 5.9 (0.04-22.5)
MNC dose (x108/kg) 5.9 (0.14-12.5) 2.8 (0.18-11.5)
CD3 dose (x108/kg) 2.3 (0.15-5.8) n¼11 2.6 (0.27-390)
n¼16
Median Engraftment
ANC > 500 13.5 (10-30) 12.5 (6-50)
Plt > 20K 16 (0-36) 16 (0-90)
Mixed T-cell Chimerism 14 13
Transplant Complications
CMV 4 5
aGVHD > grade 2 4 10
cGVHD 4 16
Death 16 14277
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Background: Hematopoietic Cell Transplant (HCT) is often
curative for patients with myelodysplastic syndrome (MDS)
or Acute Myeloid Leukemia (AML). However 20-60% of pa-
tients relapse post HCT. We aim to identify factors that pre-
dict relapse after HCT.
Methods: From 2002-2014, 63 pediatric patients underwent
HCT for AML or MDS at our institution with reduced intensity
conditioning (RIC) or myeloablative conditioning (MAC) 22 of
whom relapsed. A retrospective review of patients who did or
did not relapse was performed comparing clinical variables,chimerism, cytogenetics, ﬂow cytometry and morphology at
diagnosis, pre HCT, day 100 post HCT and at relapse.
Results: Table 1 describes patient variables. Median time
to relapse was D 210 post-HCT (20-1644). Most relapsed
early post HCT (54%, 100-365 days p¼0.008). Relapse was
more frequent in patients receiving RIC versus MAC (50%,
29%, p¼0.15) and with matched related donors versus
